Principal Investigator Arcus Biosciences Hayward, California
Herein we will present the discovery and characterization of AB680, a novel, highly potent, reversible and selective small molecule inhibitor of CD73,. The high potency of AB680 is complemented by excellent pharmacokinetic properties. AB680 has demonstrated very low clearance and long half-lives across preclinical species, resulting in a PK profile suitable for long-acting parenteral administration. AB680 is currently being evaluated in clinical development as a potential anti-tumor agent.
Upon completion, participant will be able to define the melanoma antigen gene (MAGE) family.
Upon completion, participant will be able to understand the mechanism of action for MAGE ubiquitin ligases.
Upon completion, participant will be able to explore stategies for therapeutic targeting of oncogenic MAGE ubiquitin ligases.